COMBINATION VACCINE/MICROBICIDE EFFICACY ASSESSMENT IN THE SHIV/MACAQUE MODEL

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 评价了DNA初免/rAd 5加强接种方案针对R5 SHIVSF 162 P3重复低剂量攻击的效力。多次低剂量接触更接近于自然HIV-1传播的动态，R5病毒代表了绝大多数性传播病例。将16只动物分为两组。A组8只动物，分别于0、4、8周用DNA预激2次，再用rAd 5加强1次。B组8只动物在0、4、8周时同样肌注无菌生理盐水。我们正在进行为期20周的300 TCID 50 SHIVSF 162 P3 N每周IVAG攻毒。初步结果是3/8的疫苗组和5/8的对照组被感染。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The efficacy of a DNA prime/rAd5 boost vaccination protocol against repeated low-dose challenge with R5 SHIVSF162P3 was evaluated. Multiple low-dose exposures mimic more closely the dynamics of natural HIV-1 transmission, and R5 viruses represent the vast majority of sexually transmitted cases. Sixteen animals were divided into two groups. Group A consisted 8 animals primed with DNA 2 times and boosted once with rAd5 on 0, 4 weeks and 8 weeks respectively. In Group B, 8 animals were also injected IM with a sterile saline like the experimental group on 0, 4 and 8 weeks. We are mid-way through of weekly IVAG challenges for 20 weeks with 300 TCID50 SHIVSF162P3N. Preliminary results are 3/8 of the vaccine group and 5/8 controls are infected.